Asset Details
Do you wish to reserve the book?
J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington’s disease (hd)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington’s disease (hd)
Do you wish to request the book?
J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington’s disease (hd)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington’s disease (hd)
2018
Overview
BackgroundRG6042 (formerly IONIS-HTTRx) is a non-allele-specific, huntingtin mRNA-targeting antisense oligonucleotide which reversibly suppresses production of all forms of Huntingtin protein (HTT). In a first-in-human test of this approach, RG6042 safely lowered the pathogenic mutant HTT (mHTT) in early Huntington’s disease (HD) patients, prompting Roche to begin a Global Development Program. Questions to be answered in the next phase of development include: what is the ultimate sustained magnitude of lowering of mHTT that can be achieved over long-term dosing; will lowering of mHTT be associated with clinical benefit and what are the best ways to measure such benefit; and will the approach prove to be safe and well tolerated over longer-term dosing?Method/resultsThis Global Development Program includes a single, pivotal, 24-month efficacy study designed to demonstrate clinical efficacy and safety of RG6042 in early manifest HD patients, and examine the effects on slowing or stopping clinical progression of HD. The program also includes an ongoing, open-label extension study of the completed Phase I/IIa study (NCT03342053), and an observational natural history study, both being conducted in a limited number of sites. The rationale for the target population, pivotal study design, endpoints and digital monitoring tools will be discussed.ConclusionThe Roche Global Development Program will provide valuable information on the clinical benefit and safety of the huntingtin lowering treatment RG6042 for patients with HD, as well as further longitudinal evidence of the causal role of mHTT in disease progression.
Publisher
BMJ Publishing Group LTD
Subject
